Craig Lockhart named chief of hematology and oncology at MUSC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Craig Lockhart was named chief of the Division of Hematology and Oncology in the Department of Medicine at the Medical University of South Carolina and associate director for clinical science at MUSC Hollings Cancer Center, effective April 1.

Lockhart will be replacing interim chief Michael Lilly, and will be working both on campus and remotely until he transitions to campus full time in September.

Lockhart holds several roles at the University of Miami Sylvester Comprehensive Cancer Center, including chief of the Division of Oncology and associate director for regional and strategic research affiliations. His research specialty is gastrointestinal cancers, and he has been a principal investigator on more than 100 phase I/II and III trials.

Lockhart is chief of service for oncology as part of the University of Miami Medical Group.

Prior to joining the University of Miami, Lockhart served on faculty and in leadership roles at Washington University and Siteman Cancer Center in St. Louis and at Vanderbilt University and Vanderbilt-Ingram Cancer Center in Nashville.

Lockhart has been conducting early-phase clinical trials for more than 20 years. His specific research interests are developing and conducting Phase I/II clinical trials of novel therapeutics applied to gastrointestinal cancers.

Table of Contents

YOU MAY BE INTERESTED IN

Secretary of the U.S. Department of Health and Human Services Robert F. Kennedy Jr. appeared before the House Energy and Commerce Subcommittee on Health to defend the HHS fiscal year 2026 budget proposal, and faced criticism from several Democratic lawmakers on what they described as a lack of transparency and scientific rigor in the agency’s recent decisions.

The full-scale Russian invasion of Ukraine has devastated the Ukrainian healthcare infrastructure, disrupting cancer care, halting clinical trials, and compounding long-standing systemic challenges.  Even before the war, Ukraine’s oncology system faced major constraints: Limited access to radiotherapy equipment, outdated chemotherapy supply chains, and workforce shortages. The invasion intensified these issues—cancer hospitals were damaged, warehouses destroyed,...

Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health questions. These tools, available around the clock and free from geographic or scheduling constraints, are appealing when access to medical professionals is limited by financial, language, logistical, or emotional barriers. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login